Table 4: (a) Cost categories breakdown per patient per visit (PPPV) by demographic characteristics, IV drug, and number of drugs administered per visit: sensitivity analyses using alternative definition of mSTS diagnosis1. (b) Cost categories breakdown per patient per visit (PPPV) by demographic characteristics, IV drug, and number of drugs administered per visit: sensitivity analyses excluding visits with administration costs in the top 1%1.
(a)

CategoryNo. of patientsNo. of visits TotalIV drugIV administrationOther visit-related services
Average costs ($)%Average costs ($)%Average costs ($)%Average costs ($)%

Total1,02311,7772,293.60100.0%1,334.0958.2%392.8117.1%566.7124.7%
Age
 Less than 251121,8721,067.78100.0%435.9640.8%304.4428.5%327.3830.7%
 25 to 391381,8972,077.10100.0%1,153.7255.5%439.8221.2%483.5623.3%
 40 to 542662,9992,569.69100.0%1,486.0157.8%442.2717.2%641.4125.0%
 55 to 642822,8333,159.29100.0%1,941.5861.5%438.7013.9%779.0124.7%
 Greater than 642252,1762,029.35100.0%1,263.7062.3%299.9314.8%465.7222.9%
Gender2
 Female2342,8821,971.97100.0%1,135.1257.6%332.2716.8%504.5825.6%
 Male2343,1561,856.48100.0%970.2752.3%347.3018.7%538.9129.0%
Region
 Midwest1892,2352,206.58100.0%1,292.7658.6%423.4519.2%490.3822.2%
 Northeast191992,733.61100.0%1,665.0760.9%367.4313.4%701.1125.6%
 South5136,2042,001.71100.0%1,021.9351.1%367.8118.4%611.9730.6%
 Southwest959851,620.03100.0%1,021.5063.1%308.5119.0%290.0217.9%
 West2072,1543,491.98100.0%2,388.4468.4%473.9013.6%629.6418.0%
Insurance type3
 Managed care5306,0762,773.41100.0%1,646.4659.4%492.0517.7%634.9122.9%
 Medicare2172,2001,756.68100.0%1,073.7061.1%271.1315.4%411.8623.4%
 Medicare HMO191811,808.04100.0%959.1153.0%274.8815.2%574.0531.7%
 Medicaid61756814.99100.0%282.4934.7%93.0811.4%439.4253.9%
 Medicaid HMO9141614.82100.0%233.3638.0%187.4630.5%193.9931.6%
 Indemnity558812,003.24100.0%1,200.9760.0%373.6018.6%428.6721.4%
 Other41321,5422,270.35100.0%1,211.0453.3%365.9216.1%693.3930.5%
IV drug (for mSTS)5
 Gemcitabine-based3742,9263,438.08100.0%2,551.6274.2%366.0210.6%520.4415.1%
 Anthracycline-based4061,9042,304.97100.0%1,006.5543.7%483.3421.0%815.0835.4%
 Alkylating-agents-based3833,4161,494.70100.0%498.4433.3%430.7628.8%565.5137.8%
 Angiogenesis inhibitors332505,499.09100.0%4,413.9480.3%276.565.0%808.5914.7%
 Taxane-based1419452,280.97100.0%1,371.4760.1%416.9218.3%492.5921.6%
 Other2602,3361,681.11100.0%953.2956.7%299.7617.8%428.0625.5%
Number of administered IV drugs6
 One8316,8741,717.75100.0%890.2951.8%295.1417.2%532.3231.0%
 Two5813,7793,245.44100.0%2,178.4867.1%467.9114.4%599.0518.5%
 Three1489632,449.85100.0%1,097.7744.8%696.1528.4%655.9226.8%
 Four441613,603.77100.0%1,876.4352.1%985.4927.3%741.8520.6%

1: mSTS diagnosis defined as at least two medical claims with an ICD-9-CM diagnosis code of 171 and at least one medical claims with a diagnosis of a distant secondary malignant neoplasm (ICD-9-CM 196.XX-199.0). Treatment costs derived from the contracted allowed payment for a claim.
2: 644 patients were missing gender information.
3: Insurance type is defined at the time of the index mSTS diagnosis.
4: Other includes workers' compensation, Tricare, and self-pay.
5: Gemcitabine-based includes gemcitabine monotherapy and combination therapies. Anthracycline-based includes doxorubicin and epirubicin monotherapies and combination therapies. Alkylating-agents-based includes monotherapies and combination therapies with cisplatin, cyclophosphamide, dacarbazine, etoposide, ifosfamide, temozolomide, and topotecan. Angiogenesis inhibitors include bevacizumab monotherapy. Taxane-based includes docetaxel and paclitaxel monotherapies and combination therapies. Other includes actinomycin D, carboplatin, irinotecan, interferon, oxaliplatin, vincristine, and vinorelbine.
6: Number of mSTS treatments that were administered during the visit.
(b)

CategoryNo. of patientsNo. of visits TotalIV drugIV administrationOther visit-related services
Average costs ($)%Average costs ($)%Average costs ($)%Average costs ($)%

Total1,22113,3252,363.53100.0%1,417.8760.0%376.9415.9%568.7224.1%
Age
 Less than 251161,9341,104.42100.0%459.1541.6%307.8827.9%337.3830.5%
 25 to 391511,9532,170.22100.0%1,251.4957.7%423.3519.5%495.3822.8%
 40 to 543133,3772,565.44100.0%1,521.1959.3%402.5315.7%641.7225.0%
 55 to 643443,2743,227.77100.0%2,021.8262.6%429.4513.3%776.5024.1%
 Greater than 642972,7872,112.86100.0%1,365.0864.6%299.6614.2%448.1221.2%
Gender2
 Female2893,3522,143.16100.0%1,278.4359.7%337.1615.7%527.5724.6%
 Male2953,6042,073.06100.0%1,158.9055.9%357.0117.2%557.1526.9%
Region
 Midwest2402,6362,454.05100.0%1,478.0160.2%417.5617.0%558.4822.8%
 Northeast413392,242.53100.0%1,357.2760.5%383.6417.1%501.6122.4%
 South6046,9692,084.97100.0%1,150.3655.2%347.7616.7%586.8528.1%
 Southwest1071,0621,669.85100.0%1,023.8261.3%306.2818.3%339.7520.3%
 West2292,3193,433.15100.0%2,342.7568.2%449.8513.1%640.5618.7%
Insurance type3
 Managed care6156,6472,838.48100.0%1,737.2461.2%468.5116.5%632.7322.3%
 Medicare2832,7591,875.14100.0%1,180.0662.9%270.1514.4%424.9322.7%
 Medicare HMO242511,543.22100.0%880.7057.1%241.5115.6%421.0127.3%
 Medicaid67787859.31100.0%344.7440.1%91.6110.7%422.9649.2%
 Medicaid HMO10145709.35100.0%334.7147.2%185.9426.2%188.7026.6%
 Indemnity681,0362,199.25100.0%1,359.2261.8%371.2416.9%468.8021.3%
 Other41541,7002,357.83100.0%1,259.3753.4%364.0515.4%734.4231.1%
IV drug (for mSTS)5
 Gemcitabine-based4293,3053,290.15100.0%2,439.8274.2%354.7410.8%495.5915.1%
 Anthracycline-based4231,9252,275.39100.0%1,022.9245.0%432.9719.0%819.5036.0%
 Alkylating-agents-based4193,6861,396.09100.0%441.7731.6%405.9329.1%548.3939.3%
 Angiogenesis inhibitors583675,217.74100.0%4,275.6481.9%281.205.4%660.9012.7%
 Taxane-based1721,1062,141.45100.0%1,300.2160.7%392.8718.3%448.3720.9%
 Other3482,9362,319.72100.0%1,439.0062.0%334.7714.4%545.9623.5%
Number of administered IV drugs6
 One9977,9941,842.21100.0%998.1454.2%300.7716.3%543.3029.5%
 Two6704,2293,333.67100.0%2,291.9468.8%456.6113.7%585.1117.6%
 Three1569662,353.14100.0%1,023.0143.5%613.0926.1%717.0430.5%
 Four391362,913.93100.0%1,714.2258.8%699.5724.0%500.1417.2%

1: Treatment costs derived from the contracted allowed payment for a claim.
2: 644 patients were missing gender information.
3: Insurance type is defined at the time of the index mSTS diagnosis.
4: Other includes workers' compensation, Tricare, and self-pay.
5: Gemcitabine-based includes gemcitabine monotherapy and combination therapies. Anthracycline-based includes doxorubicin and epirubicin monotherapies and combination therapies. Alkylating-agents-based includes monotherapies and combination therapies with cisplatin, cyclophosphamide, dacarbazine, etoposide, ifosfamide, temozolomide, and topotecan. Angiogenesis inhibitors include bevacizumab monotherapy. Taxane-based includes docetaxel and paclitaxel monotherapies and combination therapies. Other includes actinomycin D, carboplatin, irinotecan, interferon, oxaliplatin, vincristine, and vinorelbine.
6: Number of mSTS treatments that were administered during the visit.